Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 928 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX V XXXXXXXXX PRAVOMOCI (XX) 2020/1182

xx dne 19. xxxxxx 2020,

xxxxxx se xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx xxxx 3 přílohy XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 x xxxxxxxxxxx, označování a xxxxxx xxxxx a xxxxx

(Xxxx s xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx na Xxxxxxx x xxxxxxxxx Evropské xxxx,

x xxxxxxx na xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx x xxxxx, x xxxxx a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX x x xxxxx nařízení (XX) x. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 uvedeného xxxxxxxx,

xxxxxxxx x těmto důvodům:

(1)

Tabulka 3 x části 3 xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xxxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx nebezpečných xxxxx xx základě xxxxxxxx xxxxxxxxxxx x částech 2 xx 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře pro xxxxxxxx xxxxx („xxxxxxxx“) xxxx x xxxxxxx x xxxxxxx 37 xxxxxxxx (XX) č. 1272/2008 xxxxxxxxxx návrhy xx xxxxxxxx harmonizované xxxxxxxxxxx a xxxxxxxx xxxxxxxxx látek x xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx klasifikací a xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Na xxxxxxx xxxxxxxxxx&xxxx;(2) x těmto xxxxxxx, xxxxx vydal Xxxxx xxx posuzování xxxxx („XXX“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx zrušit xxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx xxxxxx RAC xxxx:

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxx z xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko ze xxx 8. xxxxxx 2018 ohledně xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx bis (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxxxx, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) derivátů [2],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx dibenzo[def,p]chrysenu, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 ohledně xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (ISO), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-chlor-o-tolyloxythioacetátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2S)-2-hydroxypropanové xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [formaldehyd xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx soli, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, mecetronium-ethyl-sulfátu [XXX],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, mefentriflukonazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko ze xxx 30. xxxxxxxxx 2018 ohledně 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx 2-methyl-1,2-benzothiazol-3(2H)-onu, [MBIT],

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. xxxxx 2018 xxxxxxx 5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamidu, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx iprovalikarbu (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [olej xxxxxxxx za studena xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx bez xxxxxxxx, extrahovaný superkritickým xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 ohledně dichlordioktylstannanu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [DOTE],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně olova,

—

stanovisko xx dne 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, ethylenglykol-monobutyl-etheru,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (ISO), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx azoxystrobinu (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx ze xxx 14. xxxx 2018 ohledně hymexazolu (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně hexythiazoxu (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko ze xxx 9. xxxxxx 2018 xxxxxxx pymetrozinu (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), xxxxxxx směsi: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexyl 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x látku xxxxx (xxxxx CAS 7439–92–1 x indexová xxxxx 082–013–00–1 (xxxxx x prášku; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [průměr xxxxxx ≥ 1 xx];)), XXX xx xxxx xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxx použít xxxxxxx xxxxxxxxxxxxxxx klasifikaci xx xxxxxxxxx i xxxxxxxxx xxxxx. Xxxxx xxxxxxxx k xxxxx xxxxxxxxx rozpouštění celistvé xxxxx, xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x xxxxxxxx x xxxxx environmentální klasifikaci x celistvých a xxxxxxxxxx forem jiných xxxx x xxxxxxxxxxxx xxxxxxxxx x příloze XX musí RAC xxxxxxx xxxxx xxxxxxxxx xxxx, xxx xx xxx na celistvou x práškovou xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx klasifikace. Xxxxx xxxx xxxx předloženy xxxx xxxxxxx poznatky, x nichž xxxxxxx, xx environmentální xxxxxxxxxxx xxx xxxxxxxxx formu, xxx xx xxxxxxxxxx xxxxxxxxxx výboru RAC, xxxxxx být vhodná. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx formu xxxxx xxxxxx zařazena do xxxxxxx XX xxxxxxxx (XX) č. 1272/2008, xxxxx XXX nebude xxx možnost xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx CAS 111-76-2), pro třídu xxxxxxxxxxxxx „akutní toxicita (xxxxxxxxx)“ byly xxxxxxxxxx xxxx xxxxxxx poznatky, xx kterých vyplývá, xx klasifikace xxx xxxx třídu xxxxxxxxxxxxx xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx RAC, jež xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx vhodná. Tato xxxxx nebezpečnosti xx xxxxx neměla být x příloze VI xxxxxxxx (XX) x. 1272/2008 xxxxxxx, xxxxx XXX nebude xxx xxxxxxx předložit k xxxxx novým xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; všechny xxxxxxx xxxxx xxxxxxxxxxxxx, x kterých xxxxxxxxx xxxxxxxxxx xxxxxx XXX, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx xxxxxxxx změněno.

(6)

Dodržování xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, s výhradou xxxxxxxxxxx xxxxxxxxxxxxx požadavků, xxxxxxxxxx ihned, jelikož xxxxxxxxxx potřebují xxxxxxx xxxx na xx, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx x xxxxx xxxxx xxxx revidovaným xxxxxxxxxxxx x prodali xxxxxxxxx xxxxxx. Xxxx xxxx xx rovněž nezbytná x xxxx, xxx xxxxxxxxxx xxxx xxxxxxxx xxxx přijmout xxxxxxxx xxxxx x zajištění xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx požadavků, které xxxxxxxx v xxxxxxxx xxxx provedených xxxxx xxxxxx nařízení. Tyto xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx v xx. 22 xxxx. 1 xxxx. x) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (ES) x. 1907/2006&xxxx;(3) xxxx xxxxxxxxx xxxxxxxxx x xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx xx však xxxx být xxxxxxxx, xxx xxxxx nová xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, označování x xxxxxx xxxxxxxxxx dobrovolně xxxxx xxxx xxxxxxxxxxxxx xxxxxx nařízení. To xx v xxxxxxx x přístupem xxxxx xx. 61 odst. 2 xxxxxxxx (ES) x. 1272/2008,

PŘIJALA TOTO XXXXXXXX:

Xxxxxx 1

Xxxxx nařízení (XX) x. 1272/2008

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx mění x xxxxxxx x xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx v xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje v xxxxxxxx xxxxxxxx dnem xx vyhlášení x Xxxxxxx xxxxxxxx Evropské xxxx.

Xxxxxxx xx xxx xxx 1. března 2022.

Xxxxxxxx xx druhého xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx látky x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x xxxxxx x souladu x xxxxxxxxx (ES) x. 1272/2008 xx znění xxxxxx xxxxxxxx ještě xxxxx xxxx 1. xxxxxx 2022.

Xxxx nařízení xx xxxxxxx x celém xxxxxxx a xxxxx xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. xxxxxx 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. věst. X 353, 31.12.2008, x. 1.

(2)  Stanoviska jsou xxxxxxxx na xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (ES) x. 1907/2006 ze dne 18. xxxxxxxx 2006

o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx směrnice 1999/45/ES x x zrušení xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (XX) č. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/ES (Xx. věst. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Evropského parlamentu x Xxxx (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x dodávání xxxxxxxxxx xxxxxxxxx xx trh x jejich používání

(Úř. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx VI xxxxxxxx (ES) č. 1272/2008 se tabulka 3 v xxxxx 3 mění takto:

1)

Vkládají xx tyto položky:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx koncent. xxxxxx, xxxxxxxxxxxxx xxxxxxx a XXX

Xxxxxxxx

Xxxx xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx o xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx xxxxxxx …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 A; X314: X ≥ 20 %

Xxxx Xxxx. 1X; X314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx xxxxxxx (x průměru < 3 μx, délce &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Carc. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

STOT SE 3

XXXX XX 1

Eye Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H225

H331

H301

H336

H370 (xxxxx xxxxxxx cesty, vdechnutí)

H319

H317

H400

H410

GHS02

GHS06

GHS08

GHS09

Dgr

H225

H331

H301

H336

H370 (xxxxx dýchací xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (páry)

orální: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx xxxxxx: od 0,9 xx a xx 6,0 mm; xxxxx xxxxxx: xx 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

H411

GHS09

H411“

„029-025-00-5

bis(N-hydroxy-N-nitrosocyklohexylaminato-O,O’)měď;

bis(N-cyklohexyl-diazenium-dioxy)-měď;

[Cu-HDO]

239-703-4

312600-89-8

15627-09-5

Flam. Xxx. 1

Acute Xxx. 4

XXXX XX 2

Eye Xxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: ATE = 360 xx/xx XX

X = 1

M = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, bis(koko xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1B

STOT XX 1

X360X

X372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

H350

H341

GHS08

Dgr

H350

H341

Carc. 1B; X350: C ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

STOT XX 2

Xxxxxxx Chronic 1

X360X

X302

X373 (xxx, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (oči, kůže, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Acute Xxx. 4

Xxx Xxxxx. 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx mlha)

orální: ATE = 490 xx/xx XX

X = 10

X = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Tox. 4

XXXX XX. 2

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: ATE = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX RE 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 mg/kg XX

X = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (ISO);

methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylát

–

317815-83-1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Corr. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Liq. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Skin Sens. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 mg/l (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx uvolněný x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX XX 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 xx/x (prach xxxx xxxx)

xxxxxx: XXX = 1&xxxx;100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Acute Xxx. 3

XXXX XX 2

Xxxx Irrit. 2

Xxx Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1 000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

X = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (ISO);

1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon

–

1003318-67-9

Aquatic Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Tox. 2

Xxxxx Xxx. 3

XXXX XX 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: XXX = 0,14 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 221 xx/xx TH

M = 1&xxxx;000

X = 10“

„613-334-00-2

flurochloridon (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Tox. 2

Xxxxx Tox. 4

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: ATE = 0,16 mg/l (xxxxx nebo xxxx)

xxxxxx: XXX = 567 xx/xx TH

Skin Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Acute Xxx. 3

Xxxx Corr. 1X

Xxx Xxx. 1

Skin Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 mg/kg TH

orální: XXX = 175 xx/xx XX

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

X350

X340

X372 (periferní xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (xxxxxxxxx xxxxxxx systém)“

„616-231-00-0

5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamát

–

140923-17-7

Carc. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX RE 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx ze xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

H412

H412“

2)

položky xxxxxxxxxxxx xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx xxxxxxxxx xxxxxx položkami:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Xxxxx Xxx. 1

Skin Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

H410

M = 10“

„015-134-00-5

pirimifos-methyl (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

STOT RE 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H302

H372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx systém)

H410

orální: XXX = 1&xxxx;414 xx/xx TH

M = 1&xxxx;000

X = 1 000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1B

Aquatic Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1X

Xxxxx Xxx. 2

XXXX RE 1

Xxxxxxx Xxxxxxx 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 X: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [DOTE]

239-622-4

15571-58-1

Repr. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx částic &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX H362

H410

Repr. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Tox. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Acute Tox. 3

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 xx/xx XX xxxxxx: XXX = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT XX 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

azoxystrobin (ISO);

methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Xxxxx Xxx. 3

Acute Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: ATE = 300 mg/kg XX orální: XXX = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

STOT XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Tox. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1

H330

H311

H301

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H311

H301

H314

H317

H410

EUH071

inhalační: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx TH xxxxxx: ATE = 125 xx/xx XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

hymexazol (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Xxx. 1

Skin Xxxx. 1

Aquatic Chronic 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 xx/xx XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (ISO);

reakční xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Acute Xxx. 4

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, inhalační)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H332

H302

H371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: ATE = 550 xx/xx TH

M = 10

M = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

XXXX XX 3

XXXX SE 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Dam. 1

Skin Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx dýchací xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1 100 xx/xx TH orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Perox. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 xx xxxxxxx.